These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23477159)

  • 61. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Analysis of Kudiezi injection's security literature].
    Chang YP; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2800-3. PubMed ID: 23285938
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Adverse drug reactions case reports for parenterally administered shuxuening based on analysis of literature].
    Ai QH; Wei X; Xie YM; Liao X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3190-4. PubMed ID: 24471350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial.
    Cao H; Ren M; Guo L; Shang H; Zhang J; Song Y; Wang H; Wang B; Li X; Hu J; Wang X; Wang D; Chen J; Li S; Chen L
    Trials; 2010 Mar; 11():27. PubMed ID: 20214831
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Erythroderma: A clinical-etiological study of 82 cases.
    Yuan XY; Guo JY; Dang YP; Qiao L; Liu W
    Eur J Dermatol; 2010; 20(3):373-7. PubMed ID: 20400388
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Incidence rate of adverse reaction/event by Qingkailing injection: a Meta-analysis of single rate].
    Ai CL; Xie YM; Li MQ; Wang LX; Liao X
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4770-8. PubMed ID: 27245021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Pharmacovigilance idea should be introduced sufficiently into the safety monitoring and evaluation process of Chinese drugs].
    Zhang L; Yang XH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Sep; 29(9):843-6. PubMed ID: 19960988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.
    Wester K; Jönsson A; Spigset O; Hägg S
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):173-80. PubMed ID: 16739241
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Comparison and analysis of clinical safety evaluation methods for parenterally administered Chinese medicine].
    Yan BH; Peng C; Xie YM; Wang YY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2979-82. PubMed ID: 24471315
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Analysis on 1 500 adverse reactions of Guizhi Fuling Capsules based on spontaneous response system].
    Wei RL; Xie YM; Zhang WL
    Zhongguo Zhong Yao Za Zhi; 2019 Apr; 44(7):1497-1502. PubMed ID: 31090310
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Adverse reaction induced by licorice preparations: clinical analysis of 93 cases].
    Mao M; Li W; Wang W; Wang SX; Lu J; Chang ZF
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3768-72. PubMed ID: 24494570
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
    Zhao Y; Shi C; Huang P
    Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Post-marketing surveillance of
    Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
    [No Abstract]   [Full Text] [Related]  

  • 74. [Pharmacovigilance guidelines for clinical application of Chinese patent medicines for external use].
    Cui X; Yang DQ; Xie ZN; Li YY; Wang ZF; Liu H; Liu FM; Zhao XX; Lu ZK; Wang LX; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2024 Aug; 49(16):4285-4290. PubMed ID: 39307765
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Registration study on analysis of adaptation syndromes and medication characteristics of tanreqing injection].
    Xie PY; Xie YM; Wang LX; Chang YP; You L; Zhang XL
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3571-5. PubMed ID: 25532398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Analysis of rational clinical uses of traditional Chinese medicine injections and factors influencing adverse drug reactions].
    Sun SG; Li ZF; Xie YM; Liu J; Lu Y; Song YF; Han YH; Liu LD; Peng TT
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2969-73. PubMed ID: 24471313
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Monitoring the safety of Chinese herbal medicines in Hong Kong.
    Chan TY
    Ann Pharmacother; 1996 Sep; 30(9):1039-40. PubMed ID: 8876876
    [No Abstract]   [Full Text] [Related]  

  • 78. [Building safety evidence body of shuxuetong injection].
    Jiang JJ; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3630-2. PubMed ID: 25532409
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)].
    Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients.
    Zhou Y; Yang L; Liao Z; He X; Zhou Y; Guo H
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):825-9. PubMed ID: 23510965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.